Recombinant plpro enzyme purchase - covid-19
Ended Purchase Order Awarded
- Contract number
- 75N95022P00616
- Awardee
-
BPS Bioscience Inc. UEI ZLDNP9C134F3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $24,167
Award facts
- Opportunity
-
- 75N95022Q00541 Solicitation number
- Contract value 100% obligated
- $24,167.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
- National interest action
- Coronavirus COVID-19
Award details come from SAM.gov/FPDS.
Quick answers
Who was awarded contract 75N95022P00616?
75N95022P00616 was awarded to BPS Bioscience Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 6, 2022.
How much is contract 75N95022P00616 worth?
The government has obligated $24,167 on 75N95022P00616.
Which agency awarded contract 75N95022P00616?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022P00616, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95022P00616 competed?
The extent of competition for 75N95022P00616 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award